Elanco Animal Health has patented interleukin 13 receptor subunit alpha-1/interleukin 4 receptor subunit alpha (IL13R/IL4R) polypeptides for treating IL13 and/or IL4-induced conditions in companion animals. The polypeptides are derived from canines, felines, and equines, with sequences closely matching specific IDs. GlobalData’s report on Elanco Animal Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Elanco Animal Health, NSAID cancer drugs was a key innovation area identified from patents. Elanco Animal Health's grant share as of May 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Polypeptides for treating il13 and il4-induced conditions in animals
A recently granted patent (Publication Number: US11970526B2) discloses a polypeptide with specific amino acid sequences closely related to sequences identified as SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 21, 28, 29, 30, and 31. The polypeptide may also include post-expression modifications such as glycosylation, sialyation, acetylation, or phosphorylation. Furthermore, the patent claims variations of the polypeptide that exhibit high binding affinity to IL13 and IL4 proteins in companion animal species, with dissociation constants (Kd) of less than 5×10-6 M, as determined by biolayer interferometry.
Moreover, the patent covers pharmaceutical compositions containing the disclosed polypeptides in combination with a pharmaceutically acceptable carrier. These compositions can be formulated in solid or liquid forms, providing potential applications in the development of therapeutic agents targeting IL13 and IL4 pathways in companion animals. The patent's detailed claims outline the specific amino acid sequences, modifications, and binding properties of the polypeptides, offering valuable insights for researchers and developers in the field of veterinary medicine and biopharmaceuticals.
To know more about GlobalData’s detailed insights on Elanco Animal Health, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
